Research Article

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients

Figure 1

Kaplan-Meier curve of overall survival (a) and progression-free survival (b) after bortezomib and thalidomide plus dexamethasone (VTD) induction therapy.
(a)
(b)